Quartz Bio

What Quartz Bio does

QuartzBio is a clinical-stage biopharma software company operating as a dba of Precision Regulatory and Translational Sciences, Inc., majority-owned by Precision Medicine Group through its Precision for Medicine unit, and headquartered in Baltimore, Maryland with operations in Frederick, MD and Geneva, Switzerland. The company sells an AI-enabled SaaS platform that unifies fragmented clinical trial sample, biomarker, and clinical data across multiple CROs, specialty labs, central labs, LIMS, and EDC systems, delivering real-time visibility across the biospecimen and biomarker lifecycle for pharmaceutical and biotechnology customers. The platform comprises three integrated solution modules — Sample Intelligence, Biomarker Intelligence, and Agent Intelligence — supported by sub-products including Virtual Sample Inventory Management (vSIM) and Enterprise Biomarker Data Management (eBDM), all powered by a network of domain-specific AI agents and a conversational Virtual Assistant built on fine-tuned LLMs and retrieval-augmented generation.

QuartzBio operates a subscription SaaS revenue model with quote-based enterprise pricing at the study or portfolio level, primarily distributed through a direct enterprise sales motion targeting biomarker operations, biospecimen operations, clinical operations, and translational research teams at pharmaceutical and biotechnology companies. Customers include multiple Top 5 and Top 10 pharmaceutical companies, mid-sized oncology biotechs, biologics/cell therapy developers, and large biotechs, with case-study-reported outcomes including $239K-$350K savings per Phase II/III study, 85-98% reductions in sample-related task time, and 10x faster time to insights. Go-to-market combines direct field sales, conference presence at SCOPE Summit and Bio-IT World, content marketing, webinars, and a podcast track. The platform supports 21 CFR Part 11, GxP/ICH E6(R3), HIPAA, and GDPR compliance, and is positioned around the FDA Real-Time Clinical Trial mandate.

The company's strategic trajectory is anchored by the May 2026 controlling investment from Eir Partners, with capital earmarked for platform enhancements, AI-driven automation, expanded CRO and lab interoperability, and enterprise scalability. QuartzBio has executed two acquisitions to date — SimplicityBio (2019, AI/multiomic technology) and SolveBio (2023, genomic data analytics) — and maintains a quarterly cadence of major platform releases, with v13.0.0 introducing Snowflake integration in December 2025 and the 26R1 release adding natural language search and stability monitoring in June 2026. Co-founders Scott Marshall, Ph.D. (CEO) and Tobi Guennel, PhD (CTO) continue to lead the company, supported by a CCO and operating leadership across SaaS, data management, and customer solutions.

Name

Quartz Bio

Legal name

Precision Regulatory and Translational Sciences, Inc., dba QuartzBio

Website

https://quartz.bio

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

QuartzBio sells an AI-enabled SaaS platform that unifies clinical trial sample, biomarker, and clinical data for clinical-stage pharmaceutical and biotechnology companies, using domain-specific AI agents to deliver real-time visibility and analytics across the biospecimen lifecycle.

Ownership category

akta.pro rank

Product category

Clinical Trial Bioinformatics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Clinical bioinformatics
• Biomarker intelligence
• Sample management
• Clinical trial analytics
• Precision medicine AI

Headquarters

HQ city

Genève

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SaaS/Subscription Licensing: QuartzBio operates as a SaaS platform providing subscription-based access to its Sample and Biomarker Intelligence solutions. The platform is priced per study or per portfolio basis, with enterprise agreements for pharmaceutical companies managing multiple clinical programs. Revenue is generated through recurring subscription fees with annual or multi-year contract terms.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

QuartzBio sells a vendor-agnostic, AI-enabled SaaS platform that unifies clinical trial sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem for clinical-stage biopharma. The offering is delivered through three core solutions—Sample Intelligence, Biomarker Intelligence, and Agent Intelligence—supported by Virtual Sample Inventory Management (vSIM) and Enterprise Biomarker Data Management (eBDM), sold as annual subscriptions with custom enterprise pricing.

Product overview

QuartzBio offers a unified SaaS platform for sample and biomarker intelligence in clinical-stage biopharma. The portfolio consists of the core QuartzBio Platform (the vendor-agnostic, AI-enabled infrastructure) with three integrated solution modules: Sample Intelligence for end-to-end biospecimen lifecycle management, Biomarker Intelligence for biomarker data acquisition and analysis, and Agent Intelligence powered by domain-specific AI agents. Supporting sub-products include Virtual Sample Inventory Management (vSIM) for master sample inventory tracking and Enterprise Biomarker Data Management (eBDM) for centralized biomarker data harmonization. The platform also includes a Learning Lab for training and the Precision Medicine AI Agent Platform powering all solutions with generative AI capabilities. All offerings are designed for clinical-stage biopharma managing complex sample and biomarker data ecosystems across clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• QuartzBio Platform The core vendor-agnostic, AI-enabled SaaS platform that unifies sample collection, chain of custody, consent status, metadata integrity, and biomarker results into a single ecosystem, delivering real-time visibility and control across clinical portfolios for clinical-stage biopharma companies.
• Sample Intelligence Provides 360° visibility into clinical trial samples across their entire lifecycle from collection to long-term storage, including automated sample monitoring, consent tracking, stability monitoring, and real-time discrepancy detection for clinical-stage biopharma clinical operations and biospecimen teams.
• Biomarker Intelligence Manages biomarker data across its lifecycle from data acquisition to QC, indexing, and mapping, unifying sample-related data in a centralized, harmonized platform for analysis-ready biomarker insights across multiple assay types, vendors, and file formats.
• Agent Intelligence Provides 360° insights across the sample and biomarker data ecosystem, powered by a network of domain-specific AI agents that serve as secure, personalized virtual assistants enabling conversational interaction with clinical, sample, and biomarker data for R&D teams.
• Virtual Sample Inventory Management (vSIM) A single source of truth linking samples and derivatives with clinical data, informed consent, shipping status, and more across multiple sites, labs, and repositories for comprehensive biospecimen tracking across clinical trials.
• Enterprise Biomarker Data Management (eBDM) Centralizes and harmonizes biomarker data from multiple sources with automated data ingestion, quality control, and analysis-ready dataset generation for enterprise-wide biomarker intelligence across biopharma programs.

Quantifiable outcome

• Average savings of $250K-$350K per Phase II/III study
• +6 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability12 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• SolveBiocoreStrategic or Co-development Partner · 24 January 2023SolveBio, a genomic data analytics and data analytics platform for biopharma, was acquired by QuartzBio in January 2023. The acquisition expanded QuartzBio's SaaS offerings by integrating SolveBio's enterprise data management platform for clinical sample and biomarker data. SolveBio's intelligent technologies enable mapping data as-is from any source, increasing flexibility and speeding deployment.
• SimplicityBiocoreTechnology or Integration · 6 March 2019Precision for Medicine acquired SimplicityBio in March 2019, adding artificial intelligence technology to QuartzBio's multiomic data integration and informatics platform. SimplicityBio's AI employs a unique multiomic agnostic approach for uncovering novel combinations of biomarkers. The technology was developed at Swiss university HEIG-VD and has been subject of published scientific research on AI for biomarker assessment.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva is the dominant cloud platform for life sciences, with its Veeva Vault CTMS, eTMF, and Vault Clinical suite covering EDC, CTMS, and trial management. It serves the same clinical-stage biopharma buyers as QuartzBio and could expand into sample/biomarker intelligence as part of a broader trial platform, making it the most consequential competitive incumbent.
• Medidata (Dassault Systèmes): Medidata's Rave clinical cloud provides EDC, CTMS, RTSM, and imaging/randomization for global clinical trials and serves the same enterprise pharma/biotech buyers. Its broad platform footprint and Dassault ownership position it as a credible competitor that could integrate sample/biomarker capabilities into its stack.
• Veeva Vault CTMS / eTMF: Veeva's Vault Clinical Operations suite (CTMS, eTMF, Vault CDB) is a comprehensive trial management stack used by large pharma. While broader than QuartzBio's focus, it competes head-to-head for clinical operations budget and could integrate sample/biomarker functionality over time.

Others

• Precision for Medicine: Precision for Medicine is QuartzBio's parent operating unit within Precision Medicine Group and provides CRO and biomarker laboratory services to biopharma. It is a related-party ecosystem participant that supplies samples, assays, and complementary services feeding into QuartzBio's platform.

Direct peers

• LabVantage Solutions: LabVantage is an enterprise LIMS platform used by biobanks, pharma, and clinical research organizations to manage sample lifecycles, chain of custody, and laboratory data. It competes most directly with QuartzBio's Sample Intelligence and vSIM modules for sponsor and biorepository sample inventory visibility.
• LabWare: LabWare is a leading LIMS vendor serving pharma, biotech, and clinical research laboratories with sample tracking, chain-of-custody, and compliance functionality. Its enterprise LIMS footprint overlaps with QuartzBio's Sample Intelligence on the buyer side and the sample lifecycle management use case.
• DNAnexus: DNAnexus operates a cloud-based biomedical data analysis and management platform used by pharma and clinical labs for genomics and multi-omic data at scale. It overlaps with QuartzBio's Biomarker Intelligence and eBDM in centralizing harmonized clinical-genomic data for biopharma.
• BioFortis (a Qlik company): BioFortis provides a clinical and translational research data management platform (Labmatrix) used for biospecimen, omics, and clinical data integration at pharma and academic centers. It directly competes with QuartzBio's biomarker/sample data harmonization and translational research workflows.

Emerging players

• Castor EDC: Castor offers a modern clinical data capture platform with EDC, ePRO, and eConsent modules increasingly used by mid-market and academic sponsors. It competes for the same clinical operations budgets and is expanding into broader trial data workflows adjacent to QuartzBio's platform.
• Form Bio: Form Bio is an emerging bioinformatics platform providing workflows for genomics and multi-omic data analysis in life sciences research. While more research-focused than QuartzBio's clinical-trial orientation, it competes for translational/biomarker informatics budgets at the same biotech and pharma buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubevimeo.com/quartzbio
• LinkedInlinkedin.com/company/quartz-bio
• Xx.com/quartzbio

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quartz Bio